CP
TNYA icon

Castleview Partners’s Tenaya Therapeutics TNYA Stock Holding History

Castleview Partners’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-153,137
Closed -$106K – 246
2026
Q1 		$106K Buy
+153,137
New +$113K 0.05% 194

Other funds holding TNYA

MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
EL
EWA LLC Pittsbugh, Pennsylvania $548M AUM 35.14% 1-Year Est. Return
AWM
Avior Wealth Management Omaha, Nebraska $3.8B AUM 23.28% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
VWM
Vermillion Wealth Management Rosemount, Minnesota $427M AUM 12.63% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Castleview Partners's TNYA Position: Q2 2026 in Review

Castleview Partners sold out of Tenaya Therapeutics (TNYA) in Q2 2026, closing a stake of 153,137 shares — an estimated $106K sold.

Castleview Partners first reported a position in TNYA in Q1 2026 and held it in 1 quarter. The position peaked at $106K in Q1 2026. 9 funds tracked by Wall St. Rank hold TNYA as of Q2 2026.

  • Castleview Partners reported no remaining Tenaya Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Castleview Partners sold 153,137 Tenaya Therapeutics shares in Q2 2026, an estimated $106K.
  • Castleview Partners first reported a position in Tenaya Therapeutics in Q1 2026 and held it in 1 quarter.
  • Castleview Partners's Tenaya Therapeutics position peaked at $106K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2026.

Based on Castleview Partners's 13F filing for Q2 2026, filed 20 Jul 2026.